# REVIEW ARTICLE NUTRITIONAL SUPPLEMENTS AND THEIR USE IN THE TREATMENT OF MALNUTRITION IN DEVELOPING COUNTRIES

# Sadia Fatima, Shahbaz Ali Khan\*, Fozia Fatima\*

Khyber Medical University, Peshawar, \*Ayub Medical College, Abbottabad-Pakistan

**Background:** Despite the high global prevalence of malnutrition, it remains under-treated, or undetected. The high energy nutritional supplements are usually prescribed to promote rapid weight gain. However, there is no consensus on the most effective way to treat mild to moderate malnutrition. **Methods:** For identification of articles search engines of the databases OVID, MEDLINE, EMBASE and Pub med were used for papers published from 2003 to 2014 in English language. **Results:** The total energy intake including the supplements is significantly improved. However, the rate of weight gain by the high energy nutritional supplements in moderately malnourished children is less than the expected weight gain. **Conclusion:** While assessing the impact of the supplementation on child nutritional status, other factors should also be taken into account, including appetite suppression, replacement of habitual food intake and compliance to the intervention.

**Keywords:** Severe acute malnutrition, moderate acute malnutrition, child malnutrition, ready to use foods, therapeutic nutritional products, specially formulated foods, corn-soy blend.

J Ayub Med Coll Abbottabad 2015;27(4):911–22

### Malnutrition:

#### Prevalence, causes and consequences

Malnutrition is a condition in which nutrients such as proteins, vitamins, minerals and energy are deficient or in excess (imbalance). This causes severe measurable adverse effects on body composition, function and clinical outcomes.<sup>1,2</sup> There are the controversies and confusion regarding the definition of malnutrition and its recognition. There is no universally accepted definition of malnutrition.<sup>3</sup>

It is suggested that for defining malnutrition, deficiencies of energy, protein, fat free mass, and function should be included, and for the operational definition BMI, involuntary weight loss and nutritional intake should be incorporated. Malnutrition can be explained as either over or under-nutrition with inflammation.<sup>4</sup> In this context, we are using undernutrition. The WHO cites malnutrition as the single greatest threat to the world's public health.<sup>2</sup> One out of twelve people is malnourished worldwide. According to estimates, 148 million children in the world are underweight, out of which 78 million are from South Asia and 36 million are from Sub-Saharan Africa. Approximately 19 million are severely malnourished.<sup>5</sup> Undernutrition is a direct cause of about 300,000 deaths per year and is indirectly responsible for about half of all the deaths in young children.<sup>6–8</sup>

Malnutrition is a highly pervasive and damaging condition in low and middle income countries, and is prevalent in community settings.<sup>9</sup> According to UNICEF 129 million children (25%) under 5 years of age in these countries are underweight and approximately 195 million children (28%) are stunted.<sup>10</sup> According to the UN, malnutrition kills 10 children every minute.<sup>11</sup> WHO estimates, that by 2015,

the worldwide prevalence of malnutrition will be 17.6%, and 29% of the population will have stunted growth due to under nutrition. Not surprisingly in the low income countries 112 million (20%) out of 556 million children under 5 years of age are underweight and 36 million (6.4%) are suffering from moderate wasting.<sup>12,13</sup> The data from 139 countries showed that about 10.2 % of the deaths are attributable to wasting, and wasted children have a three times higher risk of death compared to well-nourished children.9,14 South Central Asia has the highest estimated point prevalence (19%) of moderate acute malnutrition, and the highest absolute number of affected children (30 million).<sup>15</sup> In South Asian countries, the most prevalent public health issue is malnutrition among children under five years of age. It is documented that more than 50 percent of the world's malnourished children are residing in Pakistan, India and Bangladesh.<sup>16,17</sup>

The major underlying cause of malnutrition and its determinants is poverty.<sup>10,18</sup> In a given population the degree and distribution of malnutrition depends upon many factors, such as socio-economic, political, seasonal, climatic, sanitation conditions, educational level, food production, prevalence of infectious diseases, breast feeding habits, and non-availability of health services.<sup>10,18-21</sup> Poor dietary intake along with repeated infections especially in the underprivileged population is the main contributor to malnutrition. Inadequate calorie intake due to less dietary intake or decreased diet assimilation, stress due to critical acute illness, or chronic inflammation extensive burns or postoperative sepsis. gastrointestinal disease, mixed metabolic abnormalities like AIDS, cancer or chronic liver diseases are

considered to be important etiological factors for malnutrition.<sup>3,10</sup>

Despite the high global prevalence of malnutrition, it remains under-treated, or undetected. This causes an enormous detrimental effect on the health of each individual and imposes a financial burden on both the individual and the health care system.<sup>22</sup> Malnourished children are at increased risk of mortality and morbidity as compared to wellnourished children. There is an increased risk of death with increasing severity of malnutrition.<sup>10</sup> Malnutrition predisposes the body to the risk of different diseases, and also causes severe adverse outcomes of disease in a variety of ways.<sup>22</sup> Disease related malnutrition is very harmful physiologically and clinically, by delaying recovery from illnesses and impairing the quality of life.<sup>23</sup> If malnutrition is not treated or inefficiently treated, it will lead to poor quality of life of the patients, increase complications, delay recovery from diseases, result into more use of healthcare facilities, more health care expenses and more rehabilitation needs.<sup>2,3,22,24</sup> Malnutrition leads to severe adverse metabolic events which compromise the impairs body function, body's immunity, composition and its ability to acclimatize, recover and to survive.<sup>3,22</sup> Malnutrition also has severe adverse effects on the cognitive development of children, decreased productivity, reduced ability to work and small adult physique.<sup>10</sup> Taking into consideration the enormous costs of malnutrition, a condition that is largelv preventable and treatable, a timely identification followed by the most suitable, effective, efficient, evidence-based treatment is recommended.<sup>24</sup> Nutritional supplements and their use in the treatment of malnutrition in developing countries Interventions to prevent protein energy malnutrition include food supplementation, dietary diversification and fortification of salt with iodine.<sup>18</sup> Other preventive

measures include maternal nutritional education, reduction in the price of food items, high immunization coverage and correct management of infectious diseases.<sup>18</sup> In the majority of cases of malnutrition, energy intake is low therefore supplements may be given to provide extra energy and macronutrients which in turn increases the body weight.<sup>25</sup>

According to the WHO, recommendations for the treatment of malnutrition, during the nutritional rehabilitation phase the children should receive an energy and protein dense diet fortified with vitamins and minerals, to promote rapid weight gain. For this purpose, a solid, ready-to-use-food (RTUF), has been developed which is made up of peanut butter.<sup>26</sup> RTUF was developed as an alternative to the F-100 formula

or milk oil formula to be used in the hospitals and nutritional rehabilitation centres after initiation of cure.<sup>27</sup> In RTUF, the skimmed milk was replaced by groundnut paste and lacto-serum. RTUF is an energy dense paste which does not require cooking and can be stored for several months (24 months shelf life) without spoiling.<sup>28,29</sup> These RTUF have low osmolarity and can be eaten directly from the silver foil package by the child without the addition of water or milk which reduces risk of bacterial contamination.<sup>15,26</sup> In hospital settings the major limitation of RTUF is that it cannot be administered easily through a naso-gastric tube.<sup>27</sup> RTUF have the following salient features: good nutritional characteristics, low cost, resistant to bacterial contamination, long shelf life, does not need refrigeration, highly palatable, does not require any further processing, prior feeding and its consistency is suitable for feeding infants and children.<sup>27,30</sup>

Children with MAM are at three times greater risk of deaths as compared to the well-nourished children and are prone to morbidity from infectious diseases and suffer from delayed cognitive and physical development.<sup>9,31</sup>, Worldwide 11% of the children under 5 years of age are suffering from MAM.<sup>9</sup> It is estimated that in developing countries 32% (178 million) of children had weight-for-age Z score (WAZ) of less than -2.<sup>32</sup> A mildly underweight child with (WAZ) between -1.0 and -2.0 have twice the risk of death as compared with WAZ >-1.0, and the relative risk increases to five times and eight times for the moderately underweight (WAZ between -2.0 and -3.0) and severely underweight children (WAZ <-3.0), respectively.<sup>32,33</sup>

As major cause of malnutrition is reduced dietary intake, in 2006 the National Institute for Health and strategies including oral nutritional supplements, artificial nutritional support and dietary counselling. All these strategies are aimed to reverse inadequate food intake by increasing energy intake and to improve awareness, knowledge, practices and attitudes related to healthy diet.<sup>15,21</sup> Inadequate energy, protein and micronutrient intake mostly occurs in disease related malnutrition as appetite is poor due to diseases and patients ingest less food with less proteins and less nutrients, and in some cases protein requirements are also higher and there is the need for more protein to encourage damaged tissues repair and to facilitate repletion.<sup>22</sup>Clinical body Excellence (NICE) recommended an increase in dietary intake using a variety of nutrition support

The current evidence suggests that the nutritional supplements have several beneficial effects summarised in (Table-1).

|                    | functional outcomes of the oral tional supplement                     |   |  |  |   |   |  |  |  |  |  |
|--------------------|---|---|--|--|---|---|--|--|--|--|--|
| Systemic<br>Review | Study<br>design   | Patient group   | Settings   | Interventions  | No. of trials<br>No. of Patients  | Significant benefits to clinical and functional<br>outcomes with supplements  |  |  |  |  |  |
| (34)               | Systemic<br>review and<br>meta-<br>analysis                           | Adults of any<br>nutritional<br>characteristics<br>(mostly elderly<br>patients)   | Community<br>settings                                | All ONS types, energy<br>density 1.00–2.48<br>kcal/ml, (475 to 1200<br>kcal/day)<br>for 6wks - 1 yr,   | Systematic review<br>(9 RCT,<br>n=1190)<br>Meta-analysis<br>( 6 RCT, n=852) | <b>Hospital (re)admission:</b> Significant reductions with ONS vs. routine care (OR 0.59, 95% CI $0.43-0.80, P = 0.001$ )   |  |  |  |  |  |
| (35)               | Systemic<br>review and<br>meta-<br>analysis                           | Stable patients<br>with a diagnosis<br>of COPD  | All settings   | ONS and ETF  | 12 RCT (n=448)  | <b>Respiratory muscle strength:</b><br>Significantly improved with ONS<br>(pressure +3.86 standard error (SE) 1.89 cm<br>H20, $p$ =0.041; maximal<br>expiratory mouth pressure +11.85 SE 5.54 cm<br>H2O, $p$ =0.032)<br><b>Handgrip strength:</b> Significantly improved<br>(+1.35 SE 0.69 kg, $p$ = 0.05) with ONS and ETF<br><b>Weight gains</b> : Weight gain of $\geq 2$ kg with ONS.<br><b>QoL</b> : Improved with supplementation   |  |  |  |  |  |
| (22)               | Systemic<br>review and<br>meta-<br>analysis                           | Elderly with hip<br>fractures,<br>pressure ulcers,<br>COPD, cancer,<br>gastro-intestinal<br>disease, and a<br>range of critical<br>and acute<br>illnesses | Hospital and<br>community<br>settings                | ONS energy densities<br>(0.75–3.85 kcal/ml) and<br>the percentage energy<br>from protein ranged<br>from 20–54% (149 to<br>995 kcal/day)                          | 36 RCT (n=3790)   | Complications: ONS significantly reduced the<br>incidence of complications (pressure ulcers,<br>wounds, non-healing fracture, infections, or a<br>combination of complications) compared to<br>control (OR 0.68 (95% CI 0.55–0.83).<br>Functional: ONS improved grip strength<br>(1.76 kg (95% CI 0.36–3.17)<br>Energy Intake: ONS increased intake of<br>protein ( $p$ < 0.001) and energy ( $p$ < 0.001)<br>Improvements in weight: ONS significantly<br>improve weight<br>Readmissions: ONS, significantly reduce<br>hospital readmissions compared to control<br>(OR 0.59 (95% CI 0.41–0.84). |  |  |  |  |  |
| (36)               | RCT   | Malnourished<br>with benign Gl<br>disease   | Hospital   | ONS (~200ml/day)<br>for 3 months   | n=114   | QoL: Improved with ONS<br>Cost effective: Treatment is cost effective<br>according to international benchmarks  |  |  |  |  |  |
| (37)               | RCT   | Patients with<br>benign GI<br>disease   | Hospital<br>setting                                  | ONS (200 ml) per day<br>(nutritionally complete,<br>150 kcal and 10 g<br>protein/<br>100 ml, 27% energy<br>from protein) for three<br>months compared with<br>DC | n=80  | The following outcome measures significantly<br>improved with ONS as compared to DC<br>Energy intake: Total energy and protein intake<br>(p<0.0001)<br>Hand-grip<br>Strength: $26.1\pm11.3-31.5\pm10.1$ kg, $(p<0.0001)$<br>Peak flow: $329.2\pm124.0-388.9\pm108.4$ l/min<br>(p=0.004)<br>QoL: Improved<br>Hospital readmissions: Significantly less<br>(p=0.041).   |  |  |  |  |  |
| (38)               | RCT   | Patients with<br>femoral neck<br>fracture aged ≥<br>70 years  | Hospital<br>Settings                                 | Nutritional and protein<br>drinks (400 ml/day) and<br>protein-enriched meals<br>for at least 4 days<br>postoperatively during<br>hospitalization.                | n=157   | <ul> <li>Post-operative complications:</li> <li>a) Fewer patients in the intervention group developed post-operative delirium (46 patients in the intervention group, vs. 54 patients in the control group, p=0.022).</li> <li>b)The number of days with delirium was significantly fewer (p&lt;0.001) in intervention group</li> <li>c) Significantly less number of patients developed decubitus ulcers in intervention group</li> <li>d) Hospitalization period was shorter in intervention group (p=0.019)</li> </ul>   |  |  |  |  |  |
| (39)               | RCT   | Geriatric<br>patients aged<br>≥65 years<br>submitted to<br>surgery<br>for hip fracture  | Hospital settings                                    | 2 types of ONS:<br>a) 37.6 g of protein (500<br>kcal/ day)<br>b) 36 g of protein (152<br>kcal/day)   | n=90  | Small effect of ONS on serum albumin was<br>detected in patients with post-surgical<br>complications.   |  |  |  |  |  |
| (40)               | Review of<br>reviews  | Gastrointestinal<br>surgical patients   | All settings –<br>mostly<br>hospitalized<br>patients | ONS (single nutrient<br>and multi-nutrient) 250-<br>600 kcal/day for 7 days-<br>10 weeks   | 18 RCT (n=907 )<br>of ONS and ETF<br>6RCT (n=418) of<br>ONS                 | <ul> <li>Mortality: Significantly lower in supplemented<br/>group with OR 0.61 (95% CI 0.48-0.78).</li> <li>Morbidity: Supplements significantly reduced<br/>postoperative complications including wound<br/>and lung infections, postoperative ileus,<br/>unresolved peritonitis and wound dehiscence<br/>with OR 0.37 (95% CI 0.26-0.53).</li> </ul>  |  |  |  |  |  |
| (41)               | Prospectiv<br>e, double-<br>blind,<br>placebo-<br>controlled<br>trial | Acutely ill<br>elderly patients<br>aged ≥65 years   | Hospital<br>setting                                  | ONS (995 kcal/day)<br>(carbohydrate 45%, fat<br>35% and protein<br>20%) and 100% of the<br>Reference Nutrient<br>Intakes for 6 weeks                             | n=225   | Nutritional status: Serum<br>Albumin concentration, red-cell folate and<br>plasma vitamin B12 concentrations significantly<br>improved in the supplement group as compared<br>to placebo group.<br>Symptoms of depression: In the supplement<br>group there was a significant increase in the   |  |  |  |  |  |

# Table-Error! No text of specified style in document.: Summary of studies, assessing the beneficial clinical and functional outcomes of the oral tional supplement

|              | 1  |   |   |   |  | much an af nation to with no armentance of   |  |  |  |
|--------------|--|---|---|---|--|--|--|--|--|
|              |  |   |   |   |  | number of patients with no symptoms of<br>depression and a decrease in those with  |  |  |  |
|              |  |   |   |   |  | symptoms of mild or severe depression as   |  |  |  |
| (42)         |  |   |   |   |  | compared to placebo group.<br>Mortality: Improved  |  |  |  |
| (42)         | Meta-<br>analysis  | Older people<br>aged ≥65 years<br>(excluding<br>critically ill<br>patients and<br>patients<br>recovering from<br>cancer<br>treatment) | All settings  | Commercial ready-made<br>ONS and other milk-<br>based supplements 175-<br>1000 kcal/day<br>Duration of<br>Supplementation: 10<br>days –18 months  | 55 trails<br>(n=9187)  | survival with supplementation in :<br>a) Undernourished people (17 trials; 2093<br>participants) (Peto OR, 0.73 [CI, 0.56 -0.94])<br>b) People aged ≥75 years (18 trials; 1611<br>participants) (Peto OR, 0.64 [CI, 0.49 - 0.85]),<br>c) III people (22 trials; 6630 participants)<br>(Peto OR, 0.86 [CI, 0.74 - 1.00]).<br><b>Morbidity and Complications:</b> In hospitalized<br>patients supplements significantly decrease<br>complications<br>(Peto OR, 0.72 [CI, 0.53 to 0.97]) like infective<br>complications, incomplete wound healing etc.   |  |  |  |
| (43)         |  |   |   |   |  | Readmission: 29% patients in the supplements   |  |  |  |
|              | RCT  | Patients aged<br>65–92 years.   | Hospital<br>setting   | ONS (995 kcal/day) and<br>100% of the<br>Reference Nutrient for 6<br>weeks  | n=445  | group were readmitted to the hospital compared<br>with 40% in the placebo group (adjusted hazard<br>ratio 0.68 [95% CI 0.49-0.94]).<br>Mean Length of hospital stay: was 9.4 days in<br>supplement group compared with 10.1 days in<br>placebo group.<br>Nutritional Outcomes: Serum albumin<br>concentration increased significantly in the<br>supplement group   |  |  |  |
| (44)         | Sustanic   | Patients with   | Any actting (   |   |  | Biochemical outcomes: Enteral nutritional  |  |  |  |
|              | Systemic<br>review and<br>meta-<br>analysis  | chronic kidney<br>disease<br>receiving<br>maintenance<br>dialysis   | Any setting (<br>hospital,<br>outpatient or<br>home)              | ONS and enteral tube feeding  | 18 studies: RCT<br>(n=5), non-<br>RCTs <sup>13</sup>   | support increased serum albumin concentration<br>by 0.23g/dl.<br>Energy Intake: Increased total energy intake<br>Clinical outcome: May improve clinical<br>outcomes  |  |  |  |
| (45)         |  |   | All settings -  | ONS (250-500  |  | Prevention of pressure ulcers:   |  |  |  |
|              | Systemic<br>review and<br>meta-<br>analysis  | Patients with, or<br>at risk of<br>developing,<br>pressure ulcers   | mostly<br>hospitalized<br>elderly, post-<br>surgical<br>patients. | kcal/day)<br>Duration of<br>supplementation: 2–26<br>weeks  | 15 studies: RCT<br>(n=8),CCTs<br>(n=1),CTs (n=1)<br>and cohort studies<br>(n=5)  | ONS were associated with significantly lower<br>incidence of development of pressure ulcers<br>compared to routine care with OR 0.75(95% CI<br>0.62-0.89, n=1224)<br>Healing of existing pressure ulcers:<br>A tendency of improved wound healing  |  |  |  |
| (46)<br>(47) | Systemic<br>review   | Patients with<br>specific<br>diseases   | Community<br>settings   | ONS (were used in 80%<br>of the studies) with<br>energy density<br>(3·25–16·0 kJ/ml),<br>ranged from<br>< 0·42 MJ/d to > 10·5<br>MJ/d.<br>Duration of<br>supplementation: 1<br>week<br>-over 2 years. | 84 trials; 45 RCT<br>(n=1728) and<br>non-39 RCT<br>(n=842). Studies<br>grouped<br>according to<br>disease:<br>COPD (n=14),<br>Crohn's disease<br>(n=9), cystic<br>fibrosis (n=11),<br>elderly (n=12),<br>HIV and AIDS<br>(n=15); liver<br>disease (n=2),<br>malignancy<br>(n=15); other<br>conditions (n=6). | Weight change: The mean percentage weight<br>change of patients receiving ONS (2:93 %) was<br>greater than that of the control patients (1:15 %).<br>Patients with a mean<br>BMI < 20 kg/m2 had a greater percentage<br>weight change (4:7 % of the body<br>weight) than patients with a mean BMI > 20<br>kg/m2 (2:4 % of the body weight).<br>Total energy intake = 67 % of the<br>energy of the ONS consumed), which varied<br>considerably according to the disease state and<br>the BMI of patients.<br>Functional benefits:<br>COPD patients: Improved muscle strength,<br>walking distance and well-being.<br>Children with cystic fibrosis: Improved growth<br>performance.<br>Elderly: reduced falls and increased activities of<br>daily living |  |  |  |
| (48)         | RCT  | Elderly people<br>aged ≥ 65 years   | Community<br>setting (<br>private<br>nursing<br>home)             | ONS (300-500 kcal/day)<br>for 60 days   | n=88   | ONS improved:<br>a) Mini-nutritional assessment score: in<br>subjects at risk of malnutrition and in<br>malnourished subjects (from 13.9± 2.6 to<br>17.1±.9).<br>b) Weight gain: (1.4±0.5kg) in subjects at risk<br>of malnutrition and (1.5±0.4kg) in malnourished<br>subjects.   |  |  |  |
| ONIG O       | ONS, Oral nutritional supplements: RCT, Randomized controlled trial: ETF, Enteral tube feeding: OR: Odds ratio: CL Confidence interval: CCTs |   |   |   |  |  |  |  |  |

ONS, Oral nutritional supplements; RCT, Randomized controlled trial; ETF, Enteral tube feeding; OR; Odds ratio; CI, Confidence interval; CCTs, Controlled clinical trials; CTs, Clinical trials; GI disease, Gastrointestinal disease; COPD, Chronic obstructive pulmonary disease; QoL, Quality of life; DC, dietary counselling.

The evidence suggests that there was slight suppression of normal food intake with the oral nutritional supplements but they effectively increased the total energy and nutritional intake.<sup>22,23,42,49–51</sup> In one prospective randomized trial based on interviews with patients about their dietary habits and appetite, no significant difference was found in appetite between the two groups; one on the nutritional supplement, and another without the supplement, in older non-demented females with hip-fracture.<sup>52</sup> Studies have also found that

there was significantly more protein and energy intake with the supplements<sup>53</sup>, and there was no significant reduction in food intake<sup>37</sup>. A multi-centre trial to look at the effects of nutritional supplements in critically-ill elderly patients found that, whilst oral nutritional supplements increased energy and protein intake of elderly patients, the actual intake was low compared to what was expected.<sup>54</sup> Another study found that there was suppression of voluntary intake of food in the supplement group compared to controls but the total energy intake including the supplement was significantly higher in the supplement group.<sup>55</sup>

A recent meta-analysis suggested that the consumption of oral nutritional supplements could increase the daily energy intake by a mean of  $375 \text{ kcal/d}^{49}$  However; another systematic review suggested that this translated into an average total weight gain of only 1.7 kg, with wide variability (Cawood *et al*). A rare longer term trial in children and adolescents with cystic fibrosis showed no net gain in BMI (Poustie *et al*). The difference between the intake and the net weight gain thus must reflect some degree of energy compensation.<sup>55</sup>

#### Specially formulated therapeutic foods for treatment of moderate acute malnutrition in children from low- and middle-income countries

acute malnutrition Moderate (MAM) affects approximately 10% of the children under five years of age in low and middle income countries. Different approaches have been used for the nutritional recovery of the children in these settings such as lipid based nutrient supplements (food with high energy density and high lipid content) or blended foods (dry food mixtures without high lipid content), which can be provided in a low dose or full dose as a supplement to their habitual diet.<sup>15,18</sup> The provision of these supplements to MAM children increased the recovery rate by 29% and significantly improved weight-for-height as compared to standard care.1

An early study by Walker et al performed on stunted children (<-2 SD of the National Centre for Health Statistics (NCHS) reference) aged 9-24 months, were randomly assigned to four groups: a nutritional supplement group (milk based supplement providing 750 kcal per day), psychosocial stimulation group, both the supplement and stimulation group and a control group for 12 months. Supplementation significantly increased weight, head circumference, mid upper arm circumference and triceps skinfold in the first 6 months, but no significant increase was reported in the subsequent six months. In this study dietary intake was measured by two 24 hour dietary recalls before the intervention and then after 6 months of the intervention. The baseline dietary intakes were similar in the stunted and non-stunted children, while at 6 months, dietary intake was significantly reduced in the supplement group.<sup>56</sup> Lack of further improvement in weight, head circumference, mid upper arm circumference and triceps skinfold in the last six months of the study might be due to decreased food intake or/and to a decline in the intake of the supplement.

On the other hand, a study by Gershoff *et al*, observed no demonstrable changes in anthropometric indices as a result of high caloric supplementation (300 kcal) provided to pre-school children, in Thailand, from December 1981 to October 1983. No impact of supplementation on the anthropometric indices of the children in the intervention group was thought to be due to increased physical activity and reduced intake of habitual food, although neither were not measured in that study.<sup>57</sup> The disparity of the results in these studies may be due to differences in the energy density of the supplements provided and duration of the intervention.

# Ready to use foods in the treatment and prevention of moderate malnutrition

RTUF have also been used to supplement the dietary intake of the moderately malnourished<sup>58-62</sup> as shown in table-2 RTUF was found to be effective in preventing malnutrition in non-wasted children in areas of food insecurity.14,63-65 It has been recommended that the nutritional intervention to prevent malnutrition might be more effective than the curative treatment of malnutrition.<sup>66</sup> A cluster-randomized trial of children aged 6-60 months, found that 3 months of supplementation with 1 packet of RTUF per day (500 kcal/day) reduced the incidence of wasting and severe wasting over a period of 8 months of follow-up. Although, a significant reduction in the incidence of wasting was observed in the intervention group, no difference in mortality was found between the intervention and control group.<sup>64</sup> Here it is worth mentioning that two different growth standards were used in that study. For inclusion, NCHS growth standards were used while for the analysis outcomes WHO growth standards were used. In the WHO growth reference the estimates of wasting tend to decrease<sup>67</sup> and the use of WHO growth reference for analysis of outcomes may have showed exaggerated improvements in weight for height.

Similarly, Defourny *et al* evaluated a large scale distribution of ready-to-use food (RUF 1000kcal/day), during the 2007 hunger gap in Maradi region, Niger and reported that the incidence of severe acute malnutrition remained extremely low. Recovery rates were higher in approximately 60,000 moderately malnourished children who received a blanket supplementation.<sup>63</sup> Although it is important to mention here that, the moderate malnourished children consisted of a group with severe malnutrition without complications.

Similarly, Grellety *et al*, performed a non-randomized 4- months cohort study on 2238 children,

aged 6-23 months, and found a positive effect on anthropometric status as presented in table-2 and prevention of wasting by RUSF (250 kcal/day) supplementation. However, no difference in length gain was observed between the two groups. In the intervention group, fewer initially non-wasted children also developed moderate wasting compared to the group (without supplementation).<sup>68</sup> Although the baseline anthropometry of the children was not significantly different between the two groups, the children in the intervention group had slightly lower mean weight-forlength (Table-2). They were younger, and came from larger families, which might have increased the chances of sharing the supplement and could have an impact on the findings of this study. Likewise, Huybregts et al performed a cluster-randomized controlled pragmatic intervention study on 6-36 months, non-wasted children (WHZ ≥80% of NCHS reference median and absence of bilateral pitting oedema) from city Abache. The intervention group was provided with 46 grams of ready-to-use supplementary food (RUSF=247 kcal) daily for 4 months. It was found that the intervention group had significantly higher gain in height-for-age Z score, haemoglobin concentration accompanied by reduction in fever episodes, and lower risk of diarrhoea. compared to control group, at the end of the study. However, no significant differences were detected in weight increase, mean change in WHZ, between the two groups. The provision of RUSF packets in the intervention group did not result in a reduction in cumulative incidence of wasting. Compared to baseline mean WHZ increased slightly in both arms while mean HAZ was slightly lower in both arms. This study could not establish clear evidence that addition of RUSF to the household food ration was effective in the prevention of acute malnutrition.<sup>14</sup> In this study, a general food ration was also provided to both groups, which might dilute the effects of the intervention, and may be a possible reason for not finding the effect of the supplementation on nutritional status of the children in the intervention group.

For treating children with MAM, besides RTUF, other supplements, such as fortified blended flours, like corn-soy blend and corn-soy blend plus oil, and milk (CSB++) are also used.<sup>31</sup> The evidence regarding the comparison of the efficacy of RTUF with the corn-soy blend in children with MAM has conflicting results. The majority of the studies reported higher recovery rates with RTUF compared to the corn-soy blend.<sup>33,58–60,69</sup> However, other studies demonstrated that CSB++ and RTUF are equally effective.<sup>70</sup>

A randomized clinical effectiveness trial in rural Malawi, on moderately wasted children (WHZ

<-2 but  $\geq$ -3), found that 8-week intervention with milk/peanut fortified spread, soy peanut fortified spread, or corn soy blend, each providing 314 kJ/kg/day, had higher and faster recovery rates with the fortified spread groups compared to CSB group. However, no difference was detected in the rates of the length gain among three groups, and 8% of children in each group developed severe malnutrition.<sup>58</sup> Karakochuk et al performed a cluster randomized effectiveness trial on 1125 Ethiopian children aged 6-60 months with moderate acute malnutrition (MAM) (WHZ between -2 and -3). They reported that after 16 weeks of supplementation with Ready-to-use supplementary food (RUSF) 92 g (500 kcal) and corn-soy blend (CSB) 300g (1413 kcal) daily resulted in the higher recovery rate with RUSF, however this difference was not statistically significant.69

Likewise, Patel et al found greater rates of weight gain 3.1g/kg/day, higher recovery rates and lower relapse rates with RTUF than corn/soy blend (1.4g/kg/day), after 8 weeks of supplementation. Nackers et al performed a field randomized trial in Niger. Four hundred and fifty one children aged between 6 to  $\geq$ 36 months measuring 65 to <110 cm, with moderate acute malnutrition (WHM% between 70% and <80% of the NCHS median) were randomized to receive either RUTF (Plumpy' Nut 1000 kcal/day) or CSB premix (1231 kcal/day). Two hundred and fifteen children were recruited in RTUF group and 236 in the corn/soy-blend (CSB-basedpremix). Children were assessed weekly until their recovery (discharge criteria: WHM %≥85% for 2 consecutive weeks). Children who recovered after the intervention were additionally followed up for 6 months.

Although RUTF group resulted in higher weight gain, higher recovery rates (79% versus 64% in the CSB group) and shorter length of stay as compared to the CSB group, during follow up, height and height-for-age gains were similar in both groups. Also, and one fifth of the cured children relapsed.<sup>60</sup> On the other hand, a study by Lagrone *et al* reported that 12 weeks of supplementation with 75 kcal of either soy whey RUSF, soy RUSF and CSB++ are equally effective and there were no significant differences in the recovery rate of the children in each group.<sup>69</sup>

During the 12-months following period, this study demonstrated that only 63% of children who recovered from the MAM remained well-nourished, 17% relapsed to MAM and 10% developed severe acute malnutrition.<sup>31</sup>

| C . 1               | C: 1            | C 1                                   |   | malnutrition in cl  | muren                         | D F                                     |                            |                 |  |
|---------------------|-----------------|---------------------------------------|---|---|-------------------------------|---|----------------------------|-----------------|--|
| Study               | Study<br>Design | Study<br>participant                  | Intervention<br>duration  |   |                               | Results                                 |                            |                 |  |
| (14)                | Cluster         | n=1,038, non-                         | RTUF (Plumpy'   |   | Interventio                   | n                                       | Control                    | <i>p</i> -value |  |
| City of Abache      | RCT             | wasted children                       | Doz = 247   |   | (n=598)                       | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | (n=440)                    | <i>p</i> -value |  |
| Central Africa      |                 | $(\geq 80\% \text{ of})$              | kcal/day for 4  | WHZ (SD)  | -1.05 (0.93                   | )                                       | -1.09 (0.95)               |                 |  |
|                     |                 | NCHS<br>reference)                    | mths  | Intervention effect<br>(95%CI) WHZ  | -0.002 (-0.0                  |   |                            | 0.89            |  |
|                     |                 | between 6-36                          |   | HAZ (SD)  | -1.79 (1.46                   | )                                       | -2.06 (1.39)               |                 |  |
|                     |                 | mths.                                 |   | Intervention effect(95%   |                               |   | 2.00 (1.55)                | < 0.001         |  |
|                     |                 |                                       |   | CI) HAZ<br>Prevalence of stunting   | 46.2 (276)                    |   | 52.3 (230)                 |                 |  |
|                     |                 |                                       |   | (%)(n)<br>MUAC (cm)(SD)   | 14.3 (1.1)                    |   | 14.1 (1.2)                 |                 |  |
|                     |                 |                                       |   | Intervention effect(95%<br>CI) MUAC   |                               |   |                            | 0.49            |  |
| (71)                | RCT             | Underweight                           | 12 wks an average   | /   | LNS                           | CSB                                     | Control                    | <i>p</i> -value |  |
| Malawi              |                 | (WAZ<-2) age                          | daily 71 g CSB=   |   | (n=99)                        | (n=106)                                 | (n=77)                     | r               |  |
|                     |                 | 6-15 mths                             | 1188kJ or 43g<br>LNS =920kJ and                                   | ↑Weight(kg) (SD)  | 0.75 (0.41)                   | 0.68(0.50)                              | 0.63(0.40)                 | 0.21            |  |
|                     |                 |                                       | no supplement   | $\uparrow$ Length (cm) (SD)   | 3.6 (1.3)                     | 3.3(1.3)                                | 3.4(1.2)                   | 0.29            |  |
|                     |                 |                                       | (control) group.  | $\uparrow$ MUAC (cm) (SD)   | 0.4 (0.7)                     | 0.3(0.9)                                | 0.3(0.8)                   | 0.74            |  |
| 1                   |                 |                                       |   | $\triangle$ WAZ(SD)   | -0.12 (0.60                   | ) -0.13 (0.71)                          | -0.13(0.61)                | 0.40            |  |
|                     |                 |                                       |   | $\Delta$ WHZ(SD)  | -0.10(0.64)                   | -0.14 (0.81)                            | -0.25(0.71)                | 0.40            |  |
|                     |                 |                                       |   | $\Delta$ HAZ(SD)  | 0.02 (0.47)                   | -0.02 (0.47)                            | 0.06 (0.44)                | 0.45            |  |
| (72)                | RCT             | n=600                                 | P-RTUF and  |   | WPC-RU                        | TF                                      | P-RUTF                     |                 |  |
| Malawi              |                 | age 6 -59 mths                        | WPC-RTUF  |   | (n=308)                       |   | (n=292)                    |                 |  |
|                     |                 | SAM (MUAC                             | =175kcal/kg. till   | average weight gain   | 3.1                           |   | 2.9                        |                 |  |
|                     |                 | <11.0 cm or                           | recovery (weight  | (g/kg/d)  |                               |   | 0.1.00/                    |                 |  |
|                     |                 | pitting edema<br>+1 or +2).           | gain of at least<br>15%, MUAC<br>>11.0cm)                         | recovery rate   | 84.8%                         |   | 84.2%                      |                 |  |
|                     |                 |                                       |   | defaulter rate         12.2%         12.2%           Mortality rate         1.6%         0.7% |                               |   |                            |                 |  |
|                     |                 |                                       |   | Mortality rate<br>In both groups recover  |                               | SDLIEDE mir                             |                            | F > 700/        |  |
| (73)                | Prospective     | n=1331full term                       | RUCF 280 kcal or  | In bour groups recover  | RUCF                          | UNIMIX                                  | <i>p</i> - value           | l > /070.       |  |
| (75)<br>Demographic | , non           | born infants                          | UNIMIX 275 kcal   |   | (n=656)                       | (n=675)                                 | <i>p</i> -value            |                 |  |
| republic of         | blinded,        | (gestational                          | daily for six mths.   | Weight gain (kg)  | 1.2 (1.2,1.3)                 | 1.3 (1.3, 1.4)                          | 0.08                       |                 |  |
| Congo               | RCT             | age >37 weeks)                        |   | Underweight   | 20%                           | 18%                                     | 0.42                       |                 |  |
| -                   |                 | when became                           |   | Stunting  | 48%                           | 46%                                     | 0.31                       |                 |  |
|                     |                 | 4–5 mths.                             |   | Length gain (cm)  | 5.2 (5.0, 5.3)                | 5.4 (5.3, 5.6)                          | 0.039                      |                 |  |
|                     |                 |                                       |   | MUAC gain (mm)  | 5.3 (4.6, 6.1)                | 5.2 (4.5, 6.0)                          | NS                         |                 |  |
|                     |                 |                                       |   |   | -1.1 (-1.2, -1.0)             | 1.0 (-1.1, -0.9)                        | NS                         |                 |  |
|                     |                 |                                       |   | Diff WAZ ·  | -0.3 (-0.4, -0.2)             | 0.3 (-0.3, -0.2                         | ) NS                       |                 |  |
|                     |                 |                                       |   | Diff WHZ  | 0.1 (0.0, 0.2 )               | 1 (0.0, 0.2)                            | NS                         |                 |  |
| (70)                | Prospective     |                                       | 75 kcal/ kg/day of  |   | CSB++                         | Soy RUSF                                | Soy/whey RUSF              |                 |  |
| Malawi              | , RCT           | MAM (WHZ                              | CSB ++, locally   |   | (n=888)                       | (n=906)                                 | (n=918)                    |                 |  |
|                     |                 | $<-2$ and $\geq -3$ ) children aged   | produced soy<br>RUSF or an  | Weight gain (g/kg/d)  | 3.1±2.4 <sup>1</sup>          | 3.4±2.6                                 | 3.6±2.8                    |                 |  |
| 1                   |                 | 6-59 mths                             | imported  | Length gain (mm/d)  | 0.13±0.46                     | 0.13±0.44                               | 0.15±0.47                  |                 |  |
|                     |                 | 0-57 muis                             | soy/whey RUSF   | MUAC gain(mm/d)<br>WHZ  | $0.13\pm0.40^{1}$             | 0.13±0.43                               | 0.21±0.44                  |                 |  |
|                     |                 |                                       | for $\leq 12$ wks   | Recovered %(n)  | -1.68±0.67<br>85.9 (763)      | -1.61±0.63<br>87.7 (795)                | -1.59±0.60                 |                 |  |
|                     |                 |                                       |   | Develop SAM % (n)   | $\frac{85.9(763)}{6.6(59)^1}$ |   | 87.9 (807)<br>4.2 (39)     |                 |  |
|                     |                 |                                       |   | Continue MAM % (n)  |                               | 5.2 (47)<br>0.6 (5)                     | <u>4.2 (39)</u><br>0.9 (8) |                 |  |
|                     |                 |                                       |   | <sup>1</sup> SG from soy/whey R   |                               | 0.0(3)                                  | 0.9 (0)                    |                 |  |
| (69)                | Cluster         | n=1125 age 6-                         | 92 g RUSF   | SO HOLL SOY/ WIEY K   | RUSF.                         | CSB                                     | <i>p</i> -value            |                 |  |
| (09)<br>Ethiopia    | randomized      | mized 60 mths with<br>ivenes MAM (WHZ | 92 g RUSF<br>=500 kcal 300g<br>CSB =1413 kcal<br>daily for 16 wks |   | (n=351)                       | (n=698)                                 | p-value                    |                 |  |
|                     |                 |                                       |   | Recovery rate % (n)   | 73 (265)                      | 67 (482)                                | 0.056                      |                 |  |
|                     | s trial.        |                                       |   | Defaulted % (n)   | 2(7)                          | 2 (12)                                  | NS                         |                 |  |
|                     |                 | -3)                                   |   | Non responsive % (n)  | 24 (86)                       | 30 (216)                                | NS                         |                 |  |
|                     |                 |                                       |   | Met sphere target   | No                            | No                                      | -                          |                 |  |
| (74)                | RCT             | n=128,                                | RTUF 50g/ child   |   | RTUF                          | HCCM                                    | <i>p</i> -value            |                 |  |
| India               | -               | 18-59 mths                            | /day (550 cal/ 100  |   | (n=51)                        | (n=45)                                  | r                          |                 |  |
| litera              |                 | children with<br>WAZ of ≤-            | g) HCCM<br>( 187 calories/  | Weight gain (kg) 0.54   |                               | 0.38 (0.25-0.51)                        | 0.047                      |                 |  |
|                     |                 | 2SD.                                  | 100ml)  |   |                               |   |                            |                 |  |
| 1                   | 1               | 1                                     |   | 1   |                               |   |                            |                 |  |

# Table-1: Studies assessing the comparison of effectiveness of specially formulated therapeutic foods for the treatment malnutrition in children

| (59)                  | Field  | MAM                                      | RTUF =1000   |                                       | RTUF                    | (                         | SB                      | <i>p</i> -value         |
|-----------------------|--|--|--|---------------------------------------|-------------------------|---------------------------|-------------------------|-------------------------|
| South Niger           | Randomize  | (WHM%                                    | kcal/d or CSB  |                                       | (n=215                  |                           | 236)                    | <i>p</i> -value         |
| _                     | d trial  | between 70%                              | =1231 kcal/day.  | Weight gain(g/kg/d)                   | ) 5.67±3.0              | 2 4.59                    | 0±2.59                  | < 0.001                 |
|                       |  | and <80% of                              | until recovery   | MUAC gain (mm/d                       |                         |                           | ±0.24                   | 0.11                    |
|                       |  | the NCHS<br>median) age 6                | (WHM% $\geq$ 85% for 2 wks).   | LOS (weeks)                           | 4 (2-16                 |                           | 2-16)                   | < 0.001                 |
|                       |  | to $\geq$ 36 mths.                       | 101 2 WKS).  | Recovered % (n)<br>Non responder % (n | 79.1 (170               |                           | (152)                   | <0.001<br>0.25          |
| (33)                  | Clinical   | n=182                                    | 43g/day LNS  |                                       | 1) 0.0(13)              | CSB 8.9                   | (21)<br>Control         | 0.25<br><i>p</i> -value |
| (33)<br>Malawi        | randomized   | -  | =1189  kJ, 71  |                                       | n=99)                   | (n=106)                   | (n=77)                  | <i>p</i> -value         |
|                       | trial  | children (WAZ                            | Z g/day CSB<br>=921kJ control<br>group= No                                       |                                       |                         | 0.51±0.35                 | 0.47±0.35               | 0.11                    |
|                       |  | <-2) between                             |  | $\uparrow$ Length (cm) 3.             | 4±1.1                   | 3.5±1.1                   | 3.3±1.2                 | 0.60                    |
|                       |  | 6-15 mths                                |  |                                       | 2±0.8                   | -0.1±0.6                  | $0.0\pm0.6$             | 0.06                    |
|                       |  |  | supplement.  |                                       |                         | -0.31±0.59                | -0.32±0.54              | 0.03                    |
|                       |  |  |  |                                       |                         | -0.58±0.76                | $-0.55\pm0.73$          | 0.16                    |
|                       |  |  |  |                                       |                         | 0.14±0.37                 | 0.11±0.42               | 0.29                    |
|                       |  |  |  | <sup>1</sup> LNS vs Control SC        |                         |                           |                         |                         |
| (75)<br>Malani        | RCT  | 6 -18 mths with                          | 50g/d FS or  |                                       |                         | F                         | -                       | <i>p</i> -value         |
| Malawi                |  | low (WAZ < -<br>2.0)                     | 71 g/day LP for<br>12 wks.   | <b>A W :</b> 1 (1 )                   | (n=86)                  | (n=                       | ,                       | NG                      |
|                       |  | 2.0)                                     | 12 WKS.  | $\triangle$ Weight(kg)                | 0.84±0.4                |                           |                         | NS                      |
|                       |  |  |  | $\triangle$ Length (cm)               | 2.65±1.                 |                           |                         | NS                      |
|                       |  |  |  | $\triangle$ MUAC (cm)                 | 0.3±0.8                 |                           |                         | NS                      |
|                       |  |  |  | $\triangle$ WAZ                       | 0.22±0.6                |                           |                         | NS                      |
|                       |  |  |  | ∆ WHZ                                 | 0.39±0.8                |                           |                         | NS                      |
| ((0))                 | C ( 11 1   | W/ 1/ C                                  | 71 (DTUT/ 4  | $\Delta$ haz                          | -0.08±0.4               |                           |                         | NS                      |
| (60)<br>Malawi        | Controlled<br>clinical   | Weight for<br>height <85%                | 7 kg of RTUF/mth<br>and 50 kg of   |                                       |                         | <b>RTUF</b>               | CSB                     | <i>p</i> -value         |
| Ivialawi              | effectivenes   | but>80% of the                           | CSB/mth for 8<br>wks   | Rate of weight gain                   | (g/kg/d)                | (n=331)<br>3.1±2.7        | (n=41)<br>1.4±2.5       | < 0.001                 |
|                       | s trial  | international                            |  | Rate of height gain                   |                         |                           | 0.17±0.21               | 0.003                   |
|                       |  | standard.                                |  | Rate of MUAC gair                     |                         |                           | 0.18±0.29               | 0.02                    |
| (63)                  | Evaluation   | n=60,000                                 | Six monthly  | 0                                     | <b>`</b>                | RTUF                      | No RTUF                 | <i>p</i> -value         |
| Maradi                | of large<br>scale<br>distribution<br>of<br>nutritional<br>supplement<br>on | age between 6-                           | distribution of  |                                       |                         | n=3,362)                  | (n=2,949)               |                         |
|                       |  | 36 mths with a height between            | RTUF)<br>1000kcal/day for<br>children < 8kg                                      | Weight gain (g/kg/d                   |                         | 5.1±4.6                   | 5.5±4.7                 | 0.005                   |
|                       |  | 60 and 85 cm                             |  | LOS (days)                            |                         | 14.4±29.8                 | 44.4±29.6               | 0.951                   |
|                       |  |  | and 1500 kcal/day  | Cured % (n)                           | 9                       |                           | 90.1 (2621)             | 0.003                   |
|                       |  |  | for children> 8kg  | Died % (n)                            |                         | 1.8 (60)                  | 2.2 (65)                | 0.23                    |
|                       |  |  |  | Non respondent % (                    | n)                      | 1.1 (37)                  | 1.4 (41)                | 0.30                    |
|                       | prevention<br>of wasting.  |  |  |                                       |                         |                           |                         |                         |
| (64)                  | Cluster  | n= 3533                                  | RTUF   |                                       | RTUF                    | No RTUF                   | <i>p</i> -value         |                         |
| Niger                 | randomized   | children aged 6-<br>60 months with       | - (92g(500kcal/day)  |                                       | (n=1671)                | (n=1862)                  | <i>p</i> -value         |                         |
| C                     | trial  |  |  | $\triangle$ Rate of WHZ               | (11 10/1)               | (1 1002)                  | < 0.001                 |                         |
|                       |  | weight for                               |  | WHZ differences be                    | etween group            | s at baseline= -0         |                         | )3)                     |
|                       |  | height 80% or                            |  | WHZ differences be                    |                         |                           | 2 z (0.02-0.21)         |                         |
|                       |  | more of the<br>NCHS<br>reference.        |  | HAZ differences be                    | etween group            | s at baseline = -(        | 0.06z (-0.18-0.0        | )6)                     |
|                       |  |  |  | HAZ differences be                    | 0 1                     |                           | 08 (-0.18-0.06)         |                         |
|                       |  |  |  | ↓ incidence of wasti                  |                         |                           |                         |                         |
| (59)                  | D 1  | 12(2                                     |  | ↓incidence of severe                  |                         |                           | <u>(53-68%)</u>         |                         |
| <b>(58)</b><br>Malawi | Randomize<br>d clinical  | 1362<br>moderately                       | Milk/ peanut<br>FS=314kj/kg/day,   |                                       |                         | <b>Peanut FS</b><br>(465) | Soy/Peanut I<br>(n=450) | <b>CSB</b> (n=447)      |
| 1,1010 111            | effectivenes   | 2  | Soy/peanut FS  | Recovered % (n)                       |                         | (369)                     | 80 (360)                | 72 (323)                |
|                       | s trial  |  | v 1  | Remained wasted %                     |                         |                           | 7 (29)                  | 15 (67)                 |
|                       |  |  |  | WHZ at discharge                      | ~1.6=                   | ⊎0.7                      | ~1.7±0.7                | ~1.8±0.8                |
|                       |  |  |  | HAZ at discharge                      | ~2.7                    |                           | ~2.6±1.5                | ~2.8±1.9                |
|                       |  |  |  | Duration of                           | 14 (14                  | 4,42)                     | 14 (14,42)              | 28 (14,56)              |
| (76)                  | DCT  | T n=182 age<br>between 5.5-<br>6.69 mths | One year of daily<br>supplementation<br>with 50 g (FS50)<br>=256 kcal,<br>256 FS | Supplementation (d                    |                         | 1050                      | Dear                    | n                       |
| (76)<br>Malawi        | RCT  |  |  |                                       | LP<br>(n=61)            | FS50<br>(n=61)            | FS25<br>(n=60)          | <i>p</i> -value         |
|                       |  |  |  | $\triangle$ Weight(kg)                | 2.37±0.60               | 2.47±0.77                 | 2.37±0.6                | 1 0.66                  |
|                       |  |  |  | $\triangle$ Length (cm)               | 12.7±1.7                | 13.5±2.9                  | 13.2±2.9                | 0.23                    |
|                       |  |  | 25g FS<br>(FS25)=127kcal   | $\triangle$ MUAC (cm)                 | 1.1±0.9                 | $1.0\pm1.1$               | 1.0±0.8                 | 0.64                    |
|                       |  |  | or 71 g  | $\triangle$ WAZ                       | -1.29±0.63              |                           |                         |                         |
|                       |  |  | LP=282 kcal  | $\triangle$ WHZ<br>$\triangle$ HAZ    | -0.98±0.83<br>-0.74±0.9 | -1.05±0.86<br>5 -0.59±1.2 |                         |                         |
|                       |  | 1  | 1  | ца пад                                | -0./4±0.9               | J -0.39±1.2               | ∠ -0.04±0               | 0.8 0.71                |

| Ghana                                      | Community  |  | Complementary  | NB group had a sign   |   |  |   |  | 0.0.5.0  |
|--|--|--|--|---|---|--|---|--|--|
|  | based  | attending  | foods with   | LAZ (-0.20±0.54) a  |   |  |   |  | 9±0.54)  |
|  | randomized<br>trial  | weight   | SP=1sachet/d<br>NT=1 tablet/d or   | SI  |   | <u>NT</u>  | NB  |  |  |
|  | utai   | monitoring<br>session were   | NB=20g/d from  | (n=0  |   | (n=101)  | (n=97)  | (n=81)   |  |
|  |  | potentially  | 6-12 months of   | WAZ -0.53<br>HAZ -0.40±   |   | $\frac{-0.88\pm1.1^{a}}{-0.44\pm1.0}$  | -0.40±1.1 <sup>b</sup><br>-0.14±1.0   | -0.74±1.1 <sup>a,b</sup><br>-0.40±1.0  |  |
|  |  | eligible.  | age.   | WHZ -0.45±  |   | $\frac{-0.44\pm1.0}{0.89\pm1.1^{a}}$   |   | -0.40±1.0  |  |
|  |  | 5  | Ũ  | Values in the same re   |   |  |   |  |  |
| (62)                                       | RCT  | n=128  | 12 wks   | Change in WAZ sco   | $\frac{0}{2}$ Will un   | nd WHZ   | score was not signi   | ificantly different  | nt   |
| Malawi                                     |  | 6-17 mths<br>underweight<br>infants (WAZ<-<br>2, WHZ greater<br>than -3).  | supplementation 1<br>of 8 supplements,<br>nothing, 5,25,50,or<br>75g/day milk based<br>fortified spread<br>(FS), or 25, 50, or<br>75 g/day soy-based<br>fortified spread.  | between the groups.<br>Average gain in weig<br>to 75 g) than among<br>0.83 kg with 50g of 1   | ght and hei<br>those recei  | ght was hi<br>ving only  | gher among infant<br>0 to 5 g FS. The m<br>read   | s receiving FS (a<br>aximum weight   | daily 25   |
| (30)                                       | Controlled,  | n=1178   | Home based   |   |   |  | F100  | RTUF   |  |
| Malawi                                     | comparativ   | children aged  | therapy with   |   |   |  | (n=186)   | (n=992)  |  |
|  | e clinical<br>effectivenes   | between 10-60<br>mths with   | RTUF (260g<br>plastic jar/day) for   | Rate of weight gain (   |   |  | 2.0±6.9   | 3.5±3.7*   |  |
|  | s trial  | wasting (WHZ   | 8 weeks.   | Rate of height gain (   |   |  | 0.12±0.29   | 0.19±0.59*   |  |
|  | 5 11111  | <-2)   | Standard therapy   | Rate of MUAC gain   | n (mm/d) 4v   |  | ).23±0.33   | 0.32±0.41*   |  |
|  |  | _/   | (F100).  | Children died %(n)  |   |  | 5.4 (10)  | 3.0 (30)   |  |
|  |  |  | `´´  | Children relapsed %   | (n)   | 1  | 6.7 (31)  | 8.7 (87)*  |  |
| (78)                                       | RCT  | n=282 children   | RTUF, blended  |   |   | RTUF   | RTUF-S  |  | ze/soy   |
| Malawi                                     |  | >1 year old  | maize/soy flour  |   |   | (n=69)   | (n=96)  | (n=1   | 117)   |
|  |  | discharged from  | =730kJ/kg/d, or  | Average weight gain   | (ø/kø/d)  | 5.2*   | 3.1   | 3.   | ,  |
|  |  | nutrition unit   | RTUF   | Children likely to rea  |   |  | 78% 78%   |  | -  |
|  |  | were   | supplement=2100<br>kJ/d Recovery   | ,,  |   | (1.1-1.3%  |   |  |  |
|  |  | systematically<br>allocated to   | WHZ >0.  |   |   | (111 11070   | <i>.</i> )  |  |  |
| (70)                                       | DCT  | treatment  | provided   |   | - T   | IDTUE  | т   |  |  |
| (79)<br>Maawi                              | RCT  | n=260 with<br>severe<br>malnutrition   | Imported RTUF<br>or local  |   |   | I RTUF   | n   | mported RTUF   |  |
| Maawi                                      |  |  | RTUF=175   |   |   | =135)  |   | (n=125)  |  |
|  |  |  | kcal/kg/d) till they   | Weight gain (g/kg/d)  |   | ±4.6   |   | 4.8±4.0  |  |
|  |  |  | reach WHZ> -0.5  | Height gain (mm/d)  |   | 8±0.29   |   | 0.24±0.23  |  |
|  |  |  | or after 16 wks  | MUAC gain (mm/d   | ) 0.35  | 5±0.30   |   | 0.36±0.31  |  |
| (26)                                       | Open-  | n=70 severely  | The children   |   |   | I  | F100  | RTUF   |  |
| Senegal                                    | labeled<br>randomized  | malnourished   | received either 3  |   |   |  | = 30)   | (n=30)   |  |
|  |  |  | meals of F100 or   | Rate of weight gain (   |   |  | 8.7, 11.4)  | 15.6 (13.4, 17.8   |  |
|  | trial  | < -2) age 6-30   | 3 meals of RTUF  | Average duration of   |   | 17.3 (1  | 5.6,19.0)   | 13.4(12.1, 14.)  | .7)*   |
|  |  | mths   | daily ad libitum   | rehabilitation<br>Daily energy intake   |   | 5  | 73201   | 808±280*   |  |
|  |  |  |  |   |   |  |   |  | *  |
| (90)                                       |  | n= (29 (   | Dhummy?N4  | (kJ/kg body wt/d)   | 100 5 (2)   | ~~~/lr - / -l  |   | 000±200  | *  |
|  | A  | n= 628 age 6–<br>59 mths treated   | Plumpy'Nut   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (4   |   | gm/kg/da   | у.  | 000±200  |  |
| <b>(80)</b><br>Ethiopia                    | retrospectiv   | 59 mths treated  | sachets according  | (kJ/kg body wt/d)<br>Weight gain= 5.24 (4<br>Recovery rate =61.75   | 8%,   | gm/kg/day  | у.  | 000±200  | *<br>  |
|  |  |  |  | (kJ/kg body wt/d)<br>Weight gain= 5.24 (4<br>Recovery rate =61.76<br>Defaulter rate=13.85   | 8%,<br>5%   | gm/kg/day  | у.  | 0001200  |  |
|  | retrospectiv<br>e cohort   | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight   | sachets according to their body  | (kJ/kg body wt/d)<br>Weight gain= 5.24 (4<br>Recovery rate =61.73<br>Defaulter rate=13.85<br>Mortality rate= 3.029  | 8%,<br>5%<br>%  | gm/kg/day  | у.  |  | *<br>  |
|  | retrospectiv<br>e cohort   | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio   | sachets according to their body  | (kJ/kg body wt/d)<br>Weight gain= 5.24 (2<br>Recovery rate =61.76<br>Defaulter rate=13.85<br>Mortality rate= 3.029<br>Weight increase=21.   | 8%,<br>5%<br>%<br>4%  |  |   |  | *<br>  |
| <b>(80)</b><br>Ethiopia                    | retrospectiv<br>e cohort   | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight   | sachets according<br>to their body<br>weight   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (4<br>Recovery rate =61.73<br>Defaulter rate=13.85<br>Mortality rate= 3.02<br>Weight increase=21.<br>Mean length of stay   | 8%,<br>5%<br>%<br>4%<br>under inter   | vention =  | 6.48 weeks (95% (   | CI=6.25, 6.72).  | *<br>  |
| Èthiopia                                   | retrospectiv<br>e cohort<br>study  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)  | sachets according<br>to their body<br>weight   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (2<br>Recovery rate =61.76<br>Defaulter rate=13.85<br>Mortality rate= 3.029<br>Weight increase=21.   | 8%,<br>5%<br>%<br>4%<br>under inter<br>veight gain  | vention =<br>and recov   | 6.48 weeks (95% overy rate < sphere s   | CI=6.25, 6.72).<br>standards   |  |
| Èthíopia                                   | retrospectiv<br>e cohort<br>study<br>Cohort  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -  | sachets according<br>to their body<br>weight<br>RUSF   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (4<br>Recovery rate =61.73<br>Defaulter rate=13.85<br>Mortality rate= 3.02<br>Weight increase=21.<br>Mean length of stay   | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br><b>RU</b>  | vention =<br>and recov   | 6.48 weeks (95% 0<br>very rate < sphere s<br>Control  | CI=6.25, 6.72).  |  |
| Èthíopia                                   | retrospectiv<br>e cohort<br>study  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)  | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7;<br>Defaulter rate=13.8;<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of v  | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br>RU<br>(n= 1  | vention =<br>and recov<br>(SF<br>400)  | 6.48 weeks (95%)<br>very rate < sphere s<br>Control<br>(n=838)  | CI=6.25, 6.72).<br>standards   | llue   |
| Èthíopia                                   | retrospectiv<br>e cohort<br>study<br>Cohort  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths   | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7<br>Defaulter rate=13.83<br>Mortality rate= 3.029<br>Weight increase=21.<br>Mean length of stay i<br>The overall rate of v   | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br>RU<br>(n= 1<br>395 (36   | vention =<br>and recov<br>(SF<br>400)<br>54-425)   | 6.48 weeks (95%)<br>very rate < sphere s<br><b>Control</b><br>(n=838)<br>327 ( 281-372  | CI=6.25, 6.72).<br>standards   | llue<br>05   |
| Èthiopia                                   | retrospectiv<br>e cohort<br>study<br>Cohort  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -   | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7<br>Defaulter rate=13.83<br>Mortality rate= 3.029<br>Weight increase=21.<br>Mean length of stay i<br>The overall rate of v   | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br>RU<br>(n= 1  | vention =<br>and recov<br>(SF<br>400)<br>54-425)<br>6-2.8)   | 6.48 weeks (95%)<br>very rate < sphere s<br>Control<br>(n=838)  | CI=6.25, 6.72).<br>standards<br><i>p</i> -va<br>) 0.0<br>0.2   | hlue<br>05<br>24   |
| Èthíopia                                   | retrospectiv<br>e cohort<br>study<br>Cohort  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -   | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4  | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7<br>Defaulter rate=13.83<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of v<br>△ Weight (g)<br>△ Length (cm)  | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br>RU<br>(n= 1<br>395 (36<br>2.7 (2.  | vention =<br>and recov<br>(SF<br>400)<br>(4-425)<br>(6-2.8)<br>(0.2-0.2)   | 6.48 weeks (95% )<br>very rate < sphere s<br>Control<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)  | CI=6.25, 6.72).<br>standards<br><i>p</i> -va<br>) 0.0<br>0.2<br>) 0.00   | lue<br>05<br>24<br>06                                      |
| Èthiopia<br>(68)<br>Niger                  | retrospectiv<br>e cohort<br>study<br>Cohort  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645  | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF=247 kcal /  | (kJ kg body wt/d)<br>Weight gain= 5.24 (€<br>Recovery rate =61.75<br>Defaulter rate=13.85<br>Mortality rate= 3.029<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of v<br>∠ Weight (g)<br>∠ Length (cm)<br>∠ WHZ   | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br><b>RU</b><br>(n= 1<br>395 (36<br>2.7 (2.<br>-0.2 (-0   | vention =<br>and recov<br>(SF<br>400)<br>(4-425)<br>(6-2.8)<br>(0.2-0.2)   | 6.48 weeks (95% 6<br>very rate < sphere s<br>Control<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (4.7-3.3)<br>RUSF   | CI=6.25, 6.72).<br>standards<br>p-va<br>) 0.0<br>0.2<br>) 0.00<br>) 0.00<br>RTI  | llue<br>05<br>24<br>06<br>02<br>UF                         |
| Èthíopia                                   | Cohort<br>study  | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length  | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF= 247 kcal/<br>day for 6 mths,   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7;<br>Defaulter rate=13.85<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of w<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting   | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br><b>RU</b><br>(n= 1<br>395 (36<br>2.7 (2.<br>-0.2 (-0)<br>-2.8 (-3)<br>2  | vention =<br>and recov<br>(SF<br>400)<br>(4-425)<br>(6-2.8)<br>(0.2-0.2)   | 6.48 weeks (95% 6<br>very rate < sphere s<br>Control<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (-4.7-3.3)<br>RUSF<br>46% (6-69%)                                     | CI=6.25, 6.72).<br>standards<br>p-va<br>) 0.0<br>0.2<br>) 0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00 | llue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)               |
| Èthiopia<br>(68)<br>Niger<br>(65)          | Cohort<br>study<br>Cohort<br>study   | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645  | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF= 247 kcal/<br>day for 6 mths,<br>RTUF =500 kcal   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7:<br>Defaulter rate=13.83<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of v<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting<br>Incidence of wasting   | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br><b>RU</b><br>(n=1<br>395 (36<br>2.7 (2.<br>-0.2 (-0<br>-2.8 (-3  | vention =<br>and recov<br>(SF<br>400)<br>(4-425)<br>(6-2.8)<br>(0.2-0.2)   | 6.48 weeks (95% of<br>very rate < sphere s<br>Control<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>4.0 (-4.7-3.3)<br>RUSF<br>46% (6-69%)<br>NS                               | Cl=6.25, 6.72).<br>standards<br><i>p</i> -va<br>) 0.0<br>0.2<br>) 0.00<br>0.00<br>RTI<br>59% (17<br>NS   | llue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)<br>S          |
| Èthiopia<br>(68)<br>Niger<br>(65)          | Cohort<br>study<br>Cohort<br>study   | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645  | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF= 247 kcal/<br>day for 6 mths,   | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7:<br>Defaulter rate=13.83<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay i<br>The overall rate of v<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting<br>Incidence of severe v  | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br><b>RU</b><br>(n= 1<br>395 (36<br>2.7 (2.<br>-0.2 (-0<br>-2.8 (-3<br>2<br>wasting   | vention =<br>and reco<br>(SF<br>400)<br>(4-425)<br>(6-2.8)<br>(2-0.2)<br>(2-2.3)   | 6.48 weeks (95% 6<br>very rate < sphere s<br>Control<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (-4.7-3.3)<br>RUSF<br>46% (6-69%)                                     | CI=6.25, 6.72).<br>standards<br>p-va<br>) 0.0<br>0.2<br>) 0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00<br>0.00 | llue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)<br>S          |
| Èthiopia<br>(68)<br>Niger<br>(65)<br>Niger | Cohort<br>study<br>Cohort<br>study   | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645<br>age 6-36 mths   | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF=247 kcal/<br>day for 6 mths,<br>RTUF =500 kcal<br>/day for 4 mths.                      | (kJ/kg body wt/d)<br>Weight gain= 5.24 (e<br>Recovery rate =61.73<br>Defaulter rate=13.83<br>Mortality rate= 3.029<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of v<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting<br>Incidence of severe v<br>Reduction in inciden   | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br>RU<br>(n= 1<br>395 (36<br>2.7 (2.<br>-0.2 (-0<br>-2.8 (-3)<br>g<br>wasting<br>ce of stunti   | vention =<br>and recov<br>(SF<br>400)<br>54-425)<br>6-2.8)<br>0.2-0.2)<br>5.2-2.3)   | 6.48 weeks (95% (<br>very rate < sphere s<br>Control<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (4.7-3.3)<br><b>RUSF</b><br>46% (6-69%)<br>NS<br>NS                   | Cl=6.25, 6.72).<br>standards<br><i>p</i> -va<br>) 0.0<br>0.2<br>) 0.00<br>0.00<br>RTI<br>59% (17<br>NS   | llue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)<br>S          |
| Èthiopia<br>(68)<br>Niger<br>(65)          | Cohort<br>study<br>Cohort<br>study<br>Cohort<br>study<br>Cohort<br>study                                 | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645<br>age 6-36 mths<br>Care givers and                                | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF= 247 kcal /<br>day for 6 mths,<br>RTUF =500 kcal<br>/day for 4 mths.<br>149 care givers | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7;<br>Defaulter rate=13.8;<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of v<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting<br>Incidence of wasting<br>Incidence of severe v<br>Reduction in inciden<br>Expressed problems                            | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br>RU<br>(n= 1<br>395 (36<br>2.7 (2.<br>-0.2 (-0<br>-2.8 (-3)<br>2<br>wasting<br>tee of stunti<br>with accep  | vention =<br>and recov<br>(SF<br>400)<br>(34-425)<br>(6-2.8)<br>(0.2-0.2)<br>(0.2-0.2)<br>(0.2-0.2)<br>(0.2-2.3)<br>(0.2-2.3)  | 6.48 weeks (95% 6<br>very rate < sphere s<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (-4.7-3.3)<br><b>RUSF</b><br>46% (6-69%)<br>NS<br>NS<br>0%                       | Cl=6.25, 6.72).<br>standards<br><i>p</i> -va<br>) 0.0<br>0.2<br>) 0.00<br>0.00<br>RTI<br>59% (17<br>NS   | llue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)<br>S          |
| Èthiopia<br>(68)<br>Niger<br>(65)<br>Niger | Cohort<br>study<br>Cohort<br>study<br>Cohort<br>study<br>Conort<br>study                                 | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645<br>age 6-36 mths<br>Care givers and<br>community                   | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF=247 kcal/<br>day for 6 mths,<br>RTUF =500 kcal<br>/day for 4 mths.                      | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7;<br>Defaulter rate=13.8;<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of w<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting<br>Incidence of severe w<br>Reduction in incidem<br>Expressed problems<br>Perceived child dissa                           | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br><b>RU</b><br>(n=1<br>395 (36<br>2.7 (2.<br>-0.2 (-0)<br>-2.8 (-3)<br>wasting<br>wasting<br>weaking<br>with accep<br>utisfaction v  | vention =<br>and recov<br>(SF<br>400)<br>64-425)<br>6-2.8)<br>12-0.2)<br>3.2-0.2)<br>3.2-2.3)<br>ing<br>tability = (<br>vith taste =   | 6.48 weeks (95% 6<br>very rate < sphere s<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (-4.7-3.3)<br><b>RUSF</b><br>46% (6-69%)<br>NS<br>NS<br>0%                       | Cl=6.25, 6.72).<br>standards<br><i>p</i> -va<br>) 0.0<br>0.2<br>) 0.00<br>0.00<br>RTI<br>59% (17<br>NS   | llue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)<br>S          |
| Èthiopia<br>(68)<br>Niger<br>(65)<br>Niger | Cohort<br>study<br>Cohort<br>study<br>Cohort<br>study<br>Cohort<br>study<br>Cross-<br>sectional<br>semi- | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645<br>age 6-36 mths<br>Care givers and<br>community<br>health workers | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF= 247 kcal /<br>day for 6 mths,<br>RTUF =500 kcal<br>/day for 4 mths.<br>149 care givers | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7;<br>Defaulter rate=13.8;<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of w<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting<br>Incidence of severe w<br>Reduction in inciden<br>Expressed problems<br>Perceived child dissa<br>Attributed side effect | 8%,<br>5%<br>4%<br>under inter<br>veight gain<br><b>RU</b><br>(n=1<br>395 (36<br>2.7 (2.<br>-0.2 (-0<br>-2.8 (-3)<br>wasting<br>wasting<br>wasting<br>with accep<br>with accep<br>with accep<br>with accep<br>with accep<br>with stor PPN = | vention =<br>and recov<br>(SF<br>400)<br>54-425)<br>6-2.8)<br>12-0.2)<br>52-2.3)<br>ing<br>tability =<br>tability =<br>tability =<br>6-24%   | 6.48 weeks (95% 6<br>very rate < sphere s<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (-4.7-3.3)<br><b>RUSF</b><br>46% (6-69%)<br>NS<br>NS<br>0%                       | Cl=6.25, 6.72).<br>standards<br><i>p</i> -va<br>) 0.0<br>0.2<br>) 0.00<br>0.00<br>RTI<br>59% (17<br>NS   | llue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)<br>S          |
| Èthiopia<br>(68)<br>Niger<br>(65)<br>Niger | Cohort<br>study<br>Cohort<br>study<br>Cohort<br>study<br>Conort<br>study                                 | 59 mths treated<br>for SAM<br>(MUAC <110<br>cm or weight<br>for height ratio<br><70%)<br>n=2238 age 6 -<br>23 mths<br>between 60 -<br>80 cm in length<br>n=1645<br>age 6-36 mths<br>Care givers and<br>community                   | sachets according<br>to their body<br>weight<br>RUSF<br>(Plumpy'Doz) 4<br>x325 g pots (4<br>pots = 1 mth) for 4<br>mths.<br>RUSF= 247 kcal /<br>day for 6 mths,<br>RTUF =500 kcal<br>/day for 4 mths.<br>149 care givers | (kJ/kg body wt/d)<br>Weight gain= 5.24 (<br>Recovery rate =61.7;<br>Defaulter rate=13.8;<br>Mortality rate= 3.02?<br>Weight increase=21.<br>Mean length of stay<br>The overall rate of w<br>△ Weight (g)<br>△ Length (cm)<br>△ WHZ<br>△ MUAC (mm)<br>Reduction in wasting<br>Incidence of severe w<br>Reduction in incidem<br>Expressed problems<br>Perceived child dissa                           | 8%,<br>5%<br>4%<br>4%<br>under inter<br>veight gain<br><b>RU</b><br>(n= 1<br>395 (36<br>2.7 (2.<br>-0.2 (-0<br>-2.8 (-3)<br>-2.8 (-3)<br>g<br>wasting<br>ue of stunti<br>with accep<br>utisfaction V<br>tists to PPN =<br>villingly = 4     | vention =<br>and reco<br>(SF<br>400)<br>(4-425)<br>(6-2.8)<br>(2-0.2)<br>(2-2.3)<br>(2-2.3)<br>(2-2.3)<br>(2-2.3)<br>(2-2.3)<br>(2-2.3)<br>(2-2.3)<br>(2-2.3)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2-2.4)<br>(2 | 6.48 weeks (95% of<br>very rate < sphere s<br>Control<br>(n=838)<br>327 (281-372<br>2.8 (2.6-2.9)<br>-0.3 (-0.4-0.3)<br>-4.0 (-4.7-3.3)<br><b>RUSF</b><br>46% (6-69%)<br>NS<br>NS<br>00%<br>= 43% | Cl=6.25, 6.72).<br>standards $p-va$ $(-) 0.0$ $0.2$ $(-) 0.00$ $0.00$ $RTI$ $59% (17)$ $NS$ $1 \downarrow$   | lue<br>05<br>24<br>06<br>02<br>UF<br>7-80%)<br>S<br>S<br>S |

RCT, randomized control trial; P-RTUF, Peanut based RTUF; WPC-RTUF, whey protein concentrate RTUF; RUCF, Lipid based ready to use complementary foods; UNIMIX, fortified com soy blend porridge; LNS, lipid based nutrient supplement; SAM, severe acute malnutrition; MUAC, mid-upper arm circumference; RTUF, ready-to-use therapeutic food; WAZ, weight-forheight Z-score; HAZ, height-for-age Z-score; WHZ, weight-for-height Z-score; WLZ, weight-for-length Z-score; LAZ, length-for-age Z-score; CBB, com-soy blend; CSB++, com-soy blend "plus-plus"; LNS, A lipid-based nutrient supplement; RUSF, ready-to-use supplementary food; FS, fortified spread; LP, micronutrient- fortified maize-soy flour; PPN, peanut-based ready-to-use therapeutic food; HCCM, High Calorie Creal Milk; NB, Nutritabs; SP, Sprinkle powder; NI, non-intervention; LOS, Length of stay; SG, significantly different; NS, Not statistically significant; Diff, Difference; change; wks, weeks; months, mth.

## CONCLUSION

The majority of the existing evidence on the use of community based management of uncomplicated, moderately acute malnutrition has emerged from the studies conducted in Africa in emergency settings. There is little evidence exploring the impact of RTUF with other commercially available milk-based proprietary supplement in settings where food is available, and nutritional habits, nutritional education and sanitation are the main determinants of malnutrition. There are no studies on MAM from Asia where MAM is mainly prevalent. Furthermore, while assessing the impact of the supplementation on child nutritional status, other factors should also be taken into account, including appetite suppression, replacement of habitual food intake and compliance to the intervention.

### **AUTHORS' CONTRIBUTION**

SF, FF, SAK: contributed to concept development and drafted the manuscript; SF, SAK revised manuscript. None of the authors had a personal or financial conflict of interest to disclose.

## ACKNOWLEDGEMENT

This review was conducted as a part of the PhD of Dr Sadia Fatima, funded by Khyber Medical University (Pakistan).

### REFERENCES

- 1. Meier R, Stratton R. Basic concepts in nutrition: epidemiology of malnutrition. Eur J Clin Nutr Metabol 2008;3(4):e167–e70.
- Nieuwenhuizen WF, Weenen H, Rigby P, Hetherington MM. Older adults and patients in need of nutritional support: Review of current treatment options and factors influencing nutritional intake. Clin Nutr 2010;29(2):160–9.
- Alberda C, Graf A, McCargar L. Malnutrition: Etiology, consequences, and assessment of a patient at risk. Best Pract Res Clin Gastroenterol 2006;20(3):419–39.
- Meijers JM, van Bokhorst-de van der Schueren MA, Schols JM, Soeters PB, Halfens RJ. Defining malnutrition: mission or mission impossible? Nutrition 2010;26(4):432–40.
- Walton E, Allen S. Malnutrition in developing countries. Paediatr Child Health 2011;21(9):418–24.
- Nemer L, Gelband H, Jha P, Duncan T. The evidence base for interventions to reduce malnutrition in children under five and school-age children in low and middle-income countries. Commission on Macro-economics and Health, CMH Working Paper Series, Paper No WG5: 11 Geneva: WHO. 2001.
- 7. Müller O, Garenne M, Kouyaté B, Becher H. The association between protein-energy malnutrition, malaria morbidity and

all-cause mortality in West African children. Trop Med Int

Health 2003;8(6):507-11.

- Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003;361(9376):2226–34.
- Black RE, Allen LH, Bhutta ZA, Caulfield LE, De Onis M, Ezzati M, et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet 2008;371(9608):243–60.

- Imdad A, Sadiq K, Bhutta ZA. Evidence-based prevention of childhood malnutrition. Curr Opin Clin Nutr Metab Care 2011;14(3):276–85.
- Blössner M, de Onis M. Malnutrition: quantifying the health impact at national and local levels: World Health Organization Geneva; 2005.
- Golden MH. Proposed recommended nutrient densities for moderately malnourished children. Food Nutr Bull 2009;30(3 Suppl):S267–342.
- Michaelsen KF, Hoppe C, Roos N, Kaestel P, Stougaard M, Lauritzen L, *et al.* Choice of foods and ingredients for moderately malnourished children 6 months to 5 years of age. Food Nutr Bull 2009;30(3 Suppl):S343–404.
- Huybregts L, Houngbe F, Salpeteur C, Brown R, Roberfroid D, Ait-Aissa M, *et al.* The effect of adding ready-to-use supplementary food to a general food distribution on child nutritional status and morbidity: a cluster-randomized controlled trial. PLoS Med 2012;9(9):e1001313.
- Lazzerini M, Rubert L, Pani P. Specially formulated foods for treating children with moderate acute malnutrition in low- and middle-income countries. Cochrane Database Syst Rev 2013;6:CD009584.
- Hirani SA. Malnutrition in young Pakistani children. J Ayub Med Coll Abbottabad 2012;24(2):150–3.
- Gillespie SR, Haddad LJ. The double burden of malnutrition in Asia: causes, consequences, and solutions: Sage Publications India; 2003.
- Muller O, Krawinkel M. Malnutrition and health in developing countries. CMAJ 2005;173(3):279–86.
- Brabin B, Coulter J. Nutrition-associated disease. Manson's tropical diseases London: Saunders 2003:561–80.
- Grover Z, Ee LC. Protein energy malnutrition. Pediatr Clin North Am 2009;56(5):1055–68.
- 21. Young H, Borrel A, Holland D, Salama P. Public nutrition in complex emergencies. Lancet 2004;364(9448):1899–909.
- 22. Cawood AL, Elia M, Stratton RJ. Systematic review and metaanalysis of the effects of high protein oral nutritional supplements. Ageing Res Rev 2012;11(2):278–96.
- Stratton RJ, Elia M. A review of reviews: A new look at the evidence for oral nutritional supplements in clinical practice. Clin Nutr Suppl 2007;2(1):5–23.
- Stratton RJ, Elia M. Encouraging appropriate, evidence-based use of oral nutritional supplements. Proc Nutr Soc 2010;69(04):477–87.
- Lawson RM, Doshi MK, Ingoe LE, Colligan JM, Barton JR, Cobden I. Compliance of orthopaedic patients with postoperative oral nutritional supplementation. Clin Nutr 2000;19(3):171–5.
- Diop EHI, Dossou NI, Ndour MM, Briend A, Wade S. Comparison of the efficacy of a solid ready-to-use food and a liquid, milk-based diet for the rehabilitation of severely malnourished children: a randomized trial. Am J Clin Nutr 2003;78(2):302–7.
- Brewster DR. Critical appraisal of the management of severe malnutrition: 2. Dietary management. J Paediatr Child Health 2006;42(10):575–82.
- Briend A. Highly nutrient-dense spreads: a new approach to delivering multiple micronutrients to high-risk groups. Br J Nutr 2001;85(2):S175.
- Ashworth A. Efficacy and effectiveness of community-based treatment of severe malnutrition. Food Nutr Bull 2006;27(3 Suppl):S24–48.
- 30. Ciliberto MA, Sandige H, Ndekha MJ, Ashom P, Briend A, Ciliberto HM, *et al.* Comparison of home-based therapy with ready-to-use therapeutic food with standard therapy in the treatment of malnourished Malawian children: a controlled, clinical effectiveness trial. Am J Clin Nutr 2005;81(4):864–70.
- Chang CY, Trehan I, Wang RJ, Thakwalakwa C, Maleta K, Deitchler M, *et al.* Children Successfully Treated for Moderate Acute Malnutrition Remain at Risk for Malnutrition and Death in the Subsequent Year after Recovery. J Nutr 2013;143(2):215–20.

- Caulfield LE, de Onis M, Blössner M, Black RE. Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles. Am J Clin Nutr 2004;80(1):193–8.
- 33. Thakwalakwa C, Ashorn P, Phuka J, Cheung YB, Briend A, Puumalainen T, *et al.* A lipid-based nutrient supplement but not corn-soy blend modestly increases weight gain among 6-to 18month-old moderately underweight children in rural Malawi. J Nutr 2010;140(11):2008–13.
- Stratton RJ, Hebuterne X, Elia M. A systematic review and metaanalysis of the impact of oral nutritional supplements on hospital readmissions. Ageing Res Rev 2013;12(4):884–97.
- Collins PF, Elia M, Stratton RJ. Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology 2013;18(4):616–29.
- Norman K, Pirlich M, Smoliner C, Kilbert A, Schulzke JD, Ockenga J, *et al.* Cost-effectiveness of a 3-month intervention with oral nutritional supplements in disease-related malnutrition: a randomised controlled pilot study. Eur J Clin Nutr 2011;65(6):735–42.
- Norman K, Kirchner H, Freudenreich M, Ockenga J, Lochs H, Pirlich M. Three month intervention with protein and energy rich supplements improve muscle function and quality of life in malnourished patients with non-neoplastic gastrointestinal disease--a randomized controlled trial. Clin Nutr 2008;27(1):48– 56.
- Olofsson B, Stenvall M, Lundstrom M, Svensson O, Gustafson Y. Malnutrition in hip fracture patients: an intervention study. J Clin Nurs 2007;16(11):2027–38.
- Botella-Carretero JI, Íglesias B, Balsa JA, Zamarron I, Arrieta F, Vazquez C. Effects of oral nutritional supplements in normally nourished or mildly undernourished geriatric patients after surgery for hip fracture: a randomized clinical trial. JPEN J Parenter Enteral Nutr 2008;32(2):120–8.
- Stratton RJ, Elia M. Who benefits from nutritional support: what is the evidence? Eur J Gastroenterol Hepatol 2007;19(5):353–8.
- Gariballa S, Forster S. Effects of dietary supplements on depressive symptoms in older patients: A randomised doubleblind placebo-controlled trial. Clin Nutr 2007;26(5):545–51.
- 42. Milne AC, Avenell A, Potter J. Meta-analysis: protein and energy supplementation in older people. Ann Intern Med 2006;144(1):37–48.
- Gariballa S, Forster S, Walters S, Powers H. A randomized, double-blind, placebo-controlled trial of nutritional supplementation during acute illness. Am J Med 2006;119(8):693–9.
- 44. Stratton RJ, Bircher G, Fouque D, Stenvinkel P, de Mutsert R, Engfer M, et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2005;46(3):387–405.
- 45. Stratton RJ, Ek AC, Engfer M, Moore Z, Rigby P, Wolfe R, et al. Enteral nutritional support in prevention and treatment of pressure ulcers: a systematic review and meta-analysis. Ageing Res Rev 2005;4(3):422–50.
- Stratton RJ. Summary of a systematic review on oral nutritional supplement use in the community. Proc Nutr Soc 2000;59(03):469–76.
- Stratton RJ, Elia M. Are oral nutritional supplements of benefit to patients in the community? Findings from a systematic review. Curr Opin Clin Nutr Metab Care 2000;3(4):311–5.
- Lauque S, Arnaud-Battandier F, Mansourian R, Guigoz Y, Paintin M, Nourhashemi F, *et al.* Protein-energy oral supplementation in malnourished nursing-home residents. A controlled trial. Age Ageing 2000;29(1):51–6.
- Hubbard GP, Elia M, Holdoway A, Stratton RJ. A systematic review of compliance to oral nutritional supplements. Clin Nutr 2012;31(3):293–312.
- Stratton RJ, Green CJ, Elia M. Disease-related malnutrition: an evidence-based approach to treatment: Cabi; 2003.

- 51. Stratton RJ. Elucidating effective ways to identify and treat malnutrition. Proc Nutr Soc 2005;64(3):305–11.
- Carlsson P, Tidermark J, Ponzer S, Söderqvist A, Cederholm T. Food habits and appetite of elderly women at the time of a femoral neck fracture and after nutritional and anabolic support. J Hum Nutr Diet 2005;18(2):117–20.
- Edington J, Barnes R, Bryan F, Dupree E, Frost G, Hickson M, et al. A prospective randomised controlled trial of nutritional supplementation in malnourished elderly in the community: clinical and health economic outcomes. Clin Nutr 2004;23(2):195–204.
- Bourdel-Marchasson I, Barateau M, Rondeau V, Dequae-Merchadou L, Salles-Montaudon N, Emeriau JP, *et al.* A multicenter trial of the effects of oral nutritional supplementation in critically ill older inpatients. Nutrition 2000;16(1):1–5.
- Fatima S, Gerasimidis K, Wright C, Tsiountsioura M, Arvanitidou EI, Malkova D. Response of appetite and potential appetite regulators following intake of high energy nutritional supplements. Appetite 2015;95:36–43.
- Walker SP, Powell CA, Grantham-McGregor SM, Himes JH, Chang SM. Nutritional supplementation, psychosocial stimulation, and growth of stunted children: the Jamaican study. Am J Clin Nutr 1991;54(4):642–8.
- Gershoff SN, McGandy RB, Nondasuta A, Tantiwongse P. Nutrition studies in Thailand: effects of calories, nutrient supplements, and health interventions on growth of preschool Thai village children. Am J Clin Nutr 1988;48(5):1214–8.
- Matilsky DK, Maleta K, Castleman T, Manary MJ. Supplementary feeding with fortified spreads results in higher recovery rates than with a corn/soy blend in moderately wasted children. J Nnutr 2009;139(4):773–8.
- Nackers F, Broillet F, Oumarou D, Djibo A, Gaboulaud V, Guerin PJ, et al. Effectiveness of ready-to-use therapeutic food compared to a corn/soy-blend-based pre-mix for the treatment of childhood moderate acute malnutrition in Niger. J Trop Pediatr 2010;56(6):407–13.
- Patel MP, Sandige HL, Ndekha MJ, Briend A, Ashorn P, Manary MJ. Supplemental feeding with ready-to-use therapeutic food in Malawian children at risk of malnutrition. J Health, Popul Nutr 2011;23(4):351–7.
- Defourny I, Seroux G, Abdelkader I, Harczi G. Management of moderate acute malnutrition with RUTF in Niger. perspective 1994;124:2043S–6S.
- Kuusipalo H, Maleta K, Briend A, Manary M, Ashorn P. Growth and change in blood haemoglobin concentration among underweight Malawian infants receiving fortified spreads for 12 weeks: a preliminary trial. J Pediatr Gastroenterol Nutr 2006;43(4):525–32.
- 63. Defourny I, Minetti A, Harczi G, Doyon S, Shepherd S, Tectonidis M, *et al.* A large-scale distribution of milk-based fortified spreads: evidence for a new approach in regions with high burden of acute malnutrition. PLoS One 2009;4(5):e5455.
- 64. Isanaka S, Nombela N, Djibo A, Poupard M, Van Beckhoven D, Gaboulaud V, *et al.* Effect of preventive supplementation with ready-to-use therapeutic food on the nutritional status, mortality, and morbidity of children aged 6 to 60 months in Niger: a cluster randomized trial. JAMA 2009;301(3):277–85.
- Isanaka S, Roederer T, Djibo A, Luquero FJ, Nombela N, Guerin PJ, *et al.* Reducing wasting in young children with preventive supplementation: a cohort study in Niger. Pediatrics 2010;126(2):e442–50.
- Ruel MT, Menon P, Habicht JP, Loechl C, Bergeron G, Pelto G, et al. Age-based preventive targeting of food assistance and behaviour change and communication for reduction of childhood undernutrition in Haiti: a cluster randomised trial. Lancet 2008;371(9612):588–95.
- de Onis M, Garza C, Onyango AW, Borghi E. Comparison of the WHO child growth standards and the CDC 2000 growth charts. J Nutr 2007;137(1):144–8.

- Grellety E, Shepherd S, Roederer T, Manzo ML, Doyon S, Ategbo EA, *et al.* Effect of mass supplementation with ready-touse supplementary food during an anticipated nutritional emergency. PLoS One 2012;7(9):e44549.
- 69. Karakochuk C, van den Briel T, Stephens D, Zlotkin S. Treatment of moderate acute malnutrition with ready-to-use supplementary food results in higher overall recovery rates compared with a corn-soya blend in children in southerm Ethiopia: an operations research trial. Am J Clin Nutr 2012;96(4):911–6.
- LaGrone LN, Trehan I, Meuli GJ, Wang RJ, Thakwalakwa C, Maleta K, et al. A novel fortified blended flour, corn-soy blend "plus-plus," is not inferior to lipid-based ready-to-use supplementary foods for the treatment of moderate acute malnutrition in Malawian children. Am J Clin Nutr 2012;95(1):212–9.
- Thakwalakwa CM, Ashorn P, Jawati M, Phuka JC, Cheung YB, Maleta KM. An effectiveness trial showed lipid-based nutrient supplementation but not corn–soya blend offered a modest benefit in weight gain among 6-to 18-month-old underweight children in rural Malawi. Public Health Nutr 2012;15(09):1755– 62.
- Bahwere P, Banda T, Sadler K, Nyirenda G, Owino V, Shaba B, et al. Effectiveness of milk whey protein-based ready-to-use therapeutic food in treatment of severe acute malnutrition in Malawian under-5 children: a randomised, double-blind, controlled non-inferiority clinical trial. Matern Child Nutr 2014;10(3):436–51.
- 73. Bisimwa G, Owino VO, Bahwere P, Dramaix M, Donnen P, Dibari F, et al. Randomized controlled trial of the effectiveness of a soybean-maize-sorghum-based ready-to-use complementary food paste on infant growth in South Kivu, Democratic Republic of Congo. Am J Clin Nutr 2012;95(5):1157–64.
- 74. Singh AS, Kang G, Ramachandran A, Sarkar R, Peter P, Bose A. Locally made ready-to-use therapeutic food for treatment of

malnutrition: A randomized controlled trial. Indian Pediatr 2010;47(8):679-86.

75. Phuka J, Thakwalakwa C, Maleta K, Cheung YB, Briend A, Manary M, *et al.* Supplementary feeding with fortified spread

among moderately underweight 6-18-month-old rural Malawian

children. Matern Child Nutr 2009;5(2):159-70.

- Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, *et al.* Complementary feeding with fortified spread and incidence of severe stunting in 6- to 18-month-old rural Malawians. Arch Pediatr Adolesc Med 2008;162(7):619–26.
- Adu-Afarwuah S, Lartey A, Brown KH, Zlotkin S, Briend A, Dewey KG. Randomized comparison of 3 types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. Am J Clin Nutr 2007;86(2):412–20.
- Manary MJ, Ndkeha M, Ashorn P, Maleta K, Briend A. Home based therapy for severe malnutrition with ready-to-use food. Arch Dis Child 2004;89(6):557–61.
- Sandige H, Ndekha MJ, Briend A, Ashorn P, Manary MJ. Homebased treatment of malnourished Malawian children with locally produced or imported ready-to-use food. J Pediatr Gastroenterol Nutr 2004;39(2):141–6.
- Yebyo HG, Kendall C, Nigusse D, Lemma W. Outpatient therapeutic feeding program outcomes and determinants in treatment of severe acute malnutrition in tigray, northerm ethiopia: a retrospective cohort study. PLoS One 2013;8(6):e65840.
- Ali E, Zachariah R, Dahmane A, Van den Boogaard W, Shams Z, Akter T, *et al.* Peanut-based ready-to-use therapeutic food: acceptability among malnourished children and community workers in Bangladesh. Public Health Action 2013;3(2):128–35.

### Address for Correspondence:

**Dr Sadia Fatima**, Department of Biochemistry, IBMS, KMU, Peshawar,-Pakistan. **Cell:** +92 331 5812345

Email: drsadiafatima@gmail.com, drshahbazali@gmail.com